Swiss Parliament Rejects Proposal to Ban Tobacco Advertisements

Regulations by 2FIRSTS.ai
Mar.05.2024
Swiss Parliament Rejects Proposal to Ban Tobacco Advertisements
Swiss Parliament rejects proposal to ban tobacco and e-cigarette ads, sparking debate among political parties. Future uncertain.

According to persoenlich report, the Swiss parliament rejected the proposal for a ban on tobacco advertising aimed at children and adolescents, with a vote of 121 to 64 (5 abstentions). The proposal sought to completely ban the advertising of tobacco products and e-cigarettes, and had received majority support from voters in a national referendum in February 2022.

 

Currently, the proposal is set to be sent back to the Senate. If the Senate rejects it again or if the House of Representatives opposes it a second time, the proposal will come to an end. At that point, Parliament will need to come up with a new plan to implement the new constitutional provisions.

 

According to reports, there is a clear division among political parties regarding the vote on the proposal. The Swiss People's Party (SVP) criticizes the Federal Council's draft for exceeding the scope of the original proposal, believing that the law would be unenforceable and unreasonable in practice. On the other hand, the Social Democrats (SP) and the Green Party are trying to push for strict enforcement of the proposal to achieve a complete ban on tobacco advertising. They argue that the current parliamentary decision ignores the will of the people.

 

In such a division, the proposal ultimately faced rejection in the legislature.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Smoore International Reports 2025 Revenue of RMB 14.256 Billion, Up 20.8%
Smoore International Reports 2025 Revenue of RMB 14.256 Billion, Up 20.8%
On March 17, Smoore International Holdings Limited released its annual results for the year ended December 31, 2025. Revenue reached RMB 14.256 billion, up 20.8% year on year. Gross profit was RMB 4.857 billion, with a gross margin of 34.1%. Profit for the year was RMB 1.062 billion, down 18.5%, while adjusted profit for the year was RMB 1.530 billion, up 1.3%. By segment, revenue from enterprise customers was RMB 11.344 billion and revenue from own-brand business was RMB 2.912 billion.
Mar.18 by 2FIRSTS.ai
FDA Opens Public Comment Period on Draft Guidance for Flavored E-Cigarette Applications
FDA Opens Public Comment Period on Draft Guidance for Flavored E-Cigarette Applications
The U.S. Food and Drug Administration’s Center for Tobacco Products announced an open public comment period for a draft guidance titled Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications – Considerations Related to Youth Risk.
Apr.09 by 2FIRSTS.ai
Korean Vape Retailers Warn of Possible Store Closures After New Tobacco Rules Take Effect
Korean Vape Retailers Warn of Possible Store Closures After New Tobacco Rules Take Effect
South Korea’s revised Tobacco Business Act will take effect on April 24, bringing synthetic nicotine liquid vapes into the legal definition of tobacco and subjecting both retailers and manufacturers to formal regulation.
Apr.13 by 2FIRSTS.ai
PMI’s Portuguese unit to launch nicotine pouches in 2026 after tax clarification
PMI’s Portuguese unit to launch nicotine pouches in 2026 after tax clarification
After Portugal included nicotine pouches in the excise-tax (IEC) framework for tobacco and nicotine products, PMI’s Portuguese subsidiary Tabaqueira confirmed it will begin selling nicotine pouches in the country this year. The company is preparing a soft launch in two stores ahead of wider distribution, as the tax and regulatory position becomes clearer.
Mar.10 by 2FIRSTS.ai
New York Says Seized Illegal Vape Shipment Had Retail Value of USD 2.2 Million to USD 3.5 Million
New York Says Seized Illegal Vape Shipment Had Retail Value of USD 2.2 Million to USD 3.5 Million
New York state health officials said a joint operation last week involving the State Department of Health, Nassau County police and local health officials intercepted about 14 tons of illegal vape products that were intended for local distributors and smoke shops.
Mar.20 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24